Vantrexa · NSCLC · Japan · Oncology pharmacist · captured by Rachel Adeyemi on 11 Apr 2026 · reviewed by Dr. Sophie Laurent on 13 Apr 2026
Verbatim as captured; never edited
Oncology pharmacist at Osaka University Hospital raised duration of response during a scientific exchange. They requested supporting literature and a follow-up discussion.
Human-approved by Dr. Sophie Laurent on 13 Apr 2026
Duration of response: interest in collaboration reported by oncology pharmacist (JP).
helixor-private-llm-2026.05 · generated 11 Apr 2026, 10:00 UTC
AI summary
Duration of response raised by oncology pharmacist; suggest routing to Medical Affairs.
Source spans used by the model
Oncology pharmacist at Osaka University Hospital raised duration of response during a scientific exchange. They requested supporting literature and a follow-up discussion.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Diagnosis and screening | Diagnosis and screening |
| Function | Medical Affairs | Medical Affairs |
| Priority | Medium | Medium |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 3 | 20% | 12.0 |
| Strategic alignment | 2 | 20% | 8.0 |
| Scientific importance | 2 | 15% | 6.0 |
| Urgency | 1 | 15% | 3.0 |
| Novelty | 4 | 10% | 8.0 |
| Actionability | 2 | 10% | 4.0 |
| Confidence | 4 | 5% | 4.0 |
| Breadth of occurrence | 4 | 5% | 4.0 |
| Total | Medium 49 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
11 Apr 2026 · Dr. Benedikt Ivanova, Osaka University Hospital · MSL Rachel Adeyemi
Insight
Reviewed 13 Apr 2026 by Dr. Sophie Laurent
Action
Initiative
Decision
Outcome
Closure
Addressed in scientific platform update.